WCA
KRYS icon

Windsor Creek Advisors’s Krystal Biotech KRYS Stock Holding History

Windsor Creek Advisors’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-5,500
Closed -$424K – 188
2021
Q1 		$424K Buy
+5,500
New +$400K 0.11% 134

Other funds holding KRYS

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return

Windsor Creek Advisors's KRYS Position: Q2 2021 in Review

Windsor Creek Advisors sold out of Krystal Biotech (KRYS) in Q2 2021, closing a stake of 5,500 shares — an estimated $424K sold.

Windsor Creek Advisors first reported a position in KRYS in Q1 2021 and held it in 1 quarter. The position peaked at $424K in Q1 2021. 113 funds tracked by Wall St. Rank hold KRYS as of Q2 2021.

  • Windsor Creek Advisors reported no remaining Krystal Biotech position as of Q2 2021 after selling out during the quarter.
  • Windsor Creek Advisors sold 5,500 Krystal Biotech shares in Q2 2021, an estimated $424K.
  • Windsor Creek Advisors first reported a position in Krystal Biotech in Q1 2021 and held it in 1 quarter.
  • Windsor Creek Advisors's Krystal Biotech position peaked at $424K in Q1 2021.
  • 113 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2021.

Based on Windsor Creek Advisors's 13F filing for Q2 2021, filed 5 Aug 2021.